Novel Product Development Program
Engineering a Better Approach to Drug Discovery and Development
Momenta’s goal for our novel drug program is to capitalize on the structural diversity and multi-targeting potential of complex molecules to engineer drug candidates that will address key unmet medical needs in many diseases. Our novel drug research and development programs apply our proven characterization and process engineering capabilities to increase the probability of success—with a focus on both heparan-sulfate proteoglycan mimetics (HSPGs) and therapeutic proteins. We use our innovative capabilities to understand the relationship between structure and function of complex molecule drug candidates that are known to be involved in the pathogenesis of a given disease. Our capabilities to engineer improved and novel complex molecule drug and biologics candidates may have application across several diseases.
Our M402 novel oncology drug candidate is in Phase 1/2 clinical development in patients with advanced metastatic pancreatic cancer. We are also working to discover and develop additional novel drug and improved protein drug candidates by applying our innovative technology to better understand the function of these complex molecules in biological processes.
In December 2011 we acquired selected assets to sialylation technology. Sialic acid is a type of sugar modification on selected proteins that is understood to regulate anti-inflammatory and immunomodulatory function. These assets add to our core ability to modify and engineer protein backbones to precisely regulate biological networks and develop novel biologic product candidates. We may apply our proprietary sialylation technology program to develop a sialylated plasma-derived intravenous immunoglobulin, or IVIG, product, or a recombinant sialylated Fc product. We are investigating both approaches.
Last revised 5/3/2013